Triple-Negative Breast Cancer: Progress of Immune-Based Combinations and Novel Targeted Therapies

Thank you for your interest in attending the Clinical Care Options’ (CCO) symposium, “Triple-Negative Breast Cancer: The Progress of Immune-Based Combinations and Novel Targeted Therapies” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that the Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in the live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Welcome and Introduction (5 min)

Immune Checkpoint Inhibitor in Advanced TNBC (25 min)

Immune Checkpoint Inhibitor in Early-Stage TNBC (25 min)

Managing Toxicities of Immunotherapies (15 min)

Panel Discussion and Audience Question and Answer Session (15 min)

Final Thoughts and Wrap-up (5 min)


Date / Time
Event Details


Heather McArthur, MD

Associate Professor
Department of Medicine
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California

Rita Nanda, MD

Associate Professor of Medicine
Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate immunotherapies into the treatment of patients with triple-negative breast cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with triple-negative breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available data on the use of immune checkpoint inhibitor-based combinations as part of neoadjuvant/adjuvant therapy for early stage breast cancer
  • Plan first-line treatment with immune checkpoint inhibitor–based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune checkpoint inhibitors for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Recommend ongoing clinical trials assessing new therapeutic approaches for appropriate patients with triple-negative breast cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.